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Abstract
Fibrotic disorders of the lung are associated with perturbations in the plasminogen activation system. Specifically,
plasminogen activator inhibitor-1 (PAI-1) expression is increased relative to the plasminogen activators. A direct
role for this imbalance in modulating the severity of lung scarring following injury has been substantiated in the
bleomycin model of pulmonary fibrosis. However, it remains unclear whether derangements in the plasminogen
activation system contribute more generally to the pathogenesis of lung fibrosis beyond bleomycin injury. To
answer this question, we employed an alternative model of lung scarring, in which type II alveolar epithelial cells
(AECs) are specifically injured by administering diphtheria toxin (DT) to mice genetically engineered to express
the human DT receptor (DTR) off the surfactant protein C promoter. This targeted AEC injury results in the diffuse
accumulation of interstitial collagen. In the present study, we found that this targeted type II cell insult also
increases PAI-1 expression in the alveolar compartment. We identified AECs and lung macrophages to be sources
of PAI-1 production. To determine whether this elevated PAI-1 concentration was directly related to the severity
of fibrosis, DTR+ mice were crossed into a PAI-1-deficient background (DTR+: PAI-1−/−). DT administration to
DTR+: PAI-1−/− animals caused significantly less fibrosis than was measured in DTR+ mice with intact PAI-1
production. PAI-1 deficiency also abrogated the accumulation of CD11b+ exudate macrophages that were found
to express PAI-1 and type-1 collagen. These observations substantiate the critical function of PAI-1 in pulmonary
fibrosis pathogenesis and provide new insight into a potential mechanism by which this pro-fibrotic molecule
influences collagen accumulation.
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Introduction
Both acute and chronic fibrotic disorders of the
lung, including acute lung injury/acute respiratory dis-
tress syndrome (ALI/ARDS) and idiopathic pulmonary
fibrosis (IPF), are associated with significant morbid-
ity and mortality. Few treatments have been shown
to definitively modulate the severe course of these
diseases [1–4]. In ARDS, the mortality remains at
25–30% despite improvements in mechanical ventila-
tion, and 60–70% of individuals afflicted with IPF will
die within 5 years of their diagnosis [5–12]. There-
fore, it is imperative that we better understand the
pathogenic mechanisms underlying fibrosis of the lung
in order to define new treatment strategies.
Perturbations of the plasminogen activator pathway
are common in conditions associated with pulmonary
fibrosis. Specifically, in both ARDS and IPF, plasmino-
gen activation is inhibited secondary to an increased
expression of plasminogen activator inhibitor-1 (PAI-1)
relative to the plasminogen activators [13–17]. Fur-
thermore, elevated levels of PAI-1 in patients with
ALI are associated with increased mortality [18]. Ani-
mal studies using bleomycin-induced lung injury reveal
very similar derangements in plasminogen activation
[19–21]. The bleomycin model has also been used to
establish a causal link between the impairment in plas-
minogen activation and the severity of lung collagen
accumulation. In particular, restoration of plasminogen
activator activity [whether it is achieved by: (a) the
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exogenous administration of uPA; (b) increased intra-
pulmonary uPA expression; or (c) PAI-1 deficiency]
significantly decreases bleomycin-induced lung colla-
gen accumulation [22–27]. On the other hand, further
suppression of plasminogen activation through the con-
stitutive over-expression of PAI-1 significantly worsens
lung fibrosis following bleomycin injury [22].
With the exception of a single recent report, the
casual relationship between the plasminogen activa-
tion system and the extent of fibrosis that follows lung
injury has been entirely established in the bleomycin
animal model [28]. To address this shortcoming, we
tested the role of PAI-1 in the development of pul-
monary fibrosis, using a model that specifically injures
type II alveolar epithelial cells [29]. This model was
motivated by the prevalent type II cell abnormalities
seen in histopathological sections of IPF patients and
the link between type II alveolar cell-specific gene
mutations and familial pulmonary fibrosis [30–34]. In
this model, mice genetically engineered to express the
human diphtheria toxin receptor (DTR) on their type II
alveolar epithelium are given serial administrations of
diphtheria toxin (DT). In response to the DT treatment,
the DTR-expressing transgenic mice develop signifi-
cant fibrosis [29].
Here we report that a targeted insult of the type II
alveolar epithelium induces a marked increase in intra-
pulmonary PAI-1 levels. Furthermore, we demonstrate
that PAI-1 deficiency significantly attenuates the colla-
gen accumulation and mortality that results from this
specific injury. Finally, we provide evidence for a novel
mechanism, the accrual of exudate macrophages in the
lung, by which PAI-1 promotes fibrogenesis. These
observations further substantiate the role of the plas-
minogen activator system in pulmonary fibrosis and
suggest that derangements in this system could repre-
sent a common pathogenic pathway shared by the many
different causes of lung scarring.
Materials and methods
Animals
All animal experiments were performed in accordance
with institutional guidelines set forth by the University
Committee on the Use and Care of Animals (UCUCA).
Mice deficient in PAI-1 (PAI-1−/−) were supplied by
Dr Peter Carmeliet (University of Leuven, Belgium)
and had been backcrossed with C57BL/6 mice for at
least eight generations [35]. Transgenic mice express-
ing the human diphtheria toxin receptor (DTR) from a
murine SPC promoter were generated on a C57BL/6
background. These mice were repeatedly crossed with
PAI-1−/− mice to generate offspring with a single
copy of the DTR gene and that were PAI-1-deficient
(DTR+: PAI-1−/−). Control C57BL/6 mice [wild-type
(WT)] were from Jackson Laboratories (Bar Harbor,
ME, USA).
Assessment of mouse genotypes
The presence of the DTR construct and the targeted
gene deletion of PAI-1 were detected using PCR, as
previously described [25,29].
Diphtheria toxin administration
Six to eight week-old DTR+: PAI-1+/+, DTR+: PAI-
1−/−, DTR−: PAI-1+/+ (WT) and DTR−: PAI-1−/−
(PAI-1 knock-out) mice were injected i.p. with DT
once daily for 14 days at doses of 10.0 and 12.5 μg/kg.
Control mice were injected for the same duration with
100 μl PBS alone.
Bronchoalveolar lavage
BAL fluid was generated by instilling 1.0 ml sterile
PBS via a blunted 18-gauge needle into the trachea.
Recovery of the fluid was consistently 70–80% of the
total. The BAL fluid was then centrifuged at 4000 × g
for 10 min, the supernatant was removed and the
samples were stored immediately at–80 ◦C.
BAL fluid PAI-1 concentration measurements
Endogenous murine PAI-1 concentrations were mea-
sured in BAL fluid using a carboxylated microsphere-
based ELISA, as previously described [29].
Hydroxyproline assay
Hydroxyproline content of the lung was measured as
previously described [25].
Lung histology
The left lung was inflation-fixed at 25 cm H2O pres-
sure with 10% neutral-buffered formalin, removed en
bloc, further fixed in 10% neutral-buffered formalin
overnight and then paraffin-embedded. Sections (5 μm)
were stained using Masson’s trichrome, picrosirius red
and immunohistochemistry methods.
Type II alveolar epithelial cell PAI-1 expression
We measured the expression of PAI-1 by type II
alveolar epithelial cells following injury using two
different approaches: in both methods, type II AECs
were isolated as previously described [36]. In the first
assay, uninjured cells were isolated from DTR+ and
DTR− mice; 5.0 × 105 cells were plated in a 24-
well tissue culture plate. After 48 h, a subset of cells
from each genotype was exposed to DT at a dose of
1.0 μg/ml for 24 h. RNA was harvested from the cells
and PAI-1 expression was assessed via qRT–PCR and
normalized to GAPDH. PAI-1 message levels from the
treated cells were compared to untreated cells of the
same genotype. In the second assay, DTR+ and DTR−
mice were treated with DT at 10 μg/ml for 14 days. A
control group of DTR− mice was treated with PBS for
14 days. Type II AECs were isolated from each group
and 2.0 × 106 cells were cultured. After 48 h, RNA
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 228: 170–180
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
172 JJ Osterholzer et al
was harvested from the cells and PAI-1 expression was
assessed via qRT–PCR and normalized to GAPDH.
PAI-1 message levels from the DT-treated groups were
compared to the PAI-1 expression of cells from the
control mice.
Immunofluorescence for PAI-1 and SPC
Sequential co-staining was performed on sections for
surfactant protein C (SPC), followed by PAI-1. Briefly,
paraffin-embedded slides underwent antigen retrieval
with an antigen-unmasking solution. The slides were
then stained, using Universal ABC Vectastain Kit
according to the manufacturer’s instructions, and tyra-
mide fluorescence peroxidase substrates (tetramethyl-
rhodamine = red and fluorescein tyramide = green)
were used to achieve the final stain intensity. DAPI
nuclear stain was performed prior to mounting.
Tissue collection for lung leukocyte quantification
The lungs were perfused via the right heart, using PBS
containing 0.5 mM EDTA until the pulmonary ves-
sels were grossly clear. The lungs were then excised,
minced and enzymatically digested to obtain a sin-
gle cell suspension of lung leukocytes, as previously
described [37].
Antibody staining and flow cytometric analysis
Staining, including blockade of Fc receptors, and anal-
ysis by flow cytometry was performed as described
previously [37]. Specific gating strategies identify-
ing lung macrophage subpopulations (autofluorescent
CD11c+: CD11b− alveolar macrophages and autoflu-
orescent CD11c+: CD11b+ exudate macrophages and
monocyte subsets) and CD11c−: CD11b+ F4/80+ Ly-
6Chigh monocytes [38]. Intracellular staining for type-1
collagen was performed as previously reported [38,39].
Macrophage isolation
Total lung leukocytes were obtained (as above) from
the lungs of individual DT-treated DTR− mice (n = 3)
or DTR+ mice (n = 3) mice following 14 days of
DT treatment. Lung leukocytes from each strain of
mice were then pooled and subjected to fluorescence-
activated cell sorting to isolate specific macrophage
subsets to > 95% purity, using the same antibody
staining and gating strategies previously described
[38,39].
RT–PCR
Total macrophage RNA was prepared and specific
gene expression assessed using a previously described
protocol [38].
Statistical analysis
The data are presented as mean ± standard error of the
mean (SEM). Statistics were performed using Graph-
Pad Prism software. Mean values from the different
groups were compared using a one-way analysis of
variance with post hoc pairwise comparisons using the
Newman–Kuels Multiple Comparison Test. p < 0.05
was considered statistically significant.
Results
BAL fluid PAI-1 concentration in DT-treated
DTR-expressing mice
To determine whether targeted type II cell injury
induces PAI-1 expression, DT was injected for 14 days
into either WT control mice (DTR−) or DTR-
expressing mice (DTR+). WT mice injected with i.p.
PBS served as an additional control. Following the last
injection on day 14, BAL fluid was collected from each
animal and the concentration of PAI-1 was analysed.
As demonstrated in Figure 1, DT treatment caused a
significant three- to four-fold increase in PAI-1 lev-
els in the DTR+ mice compared to the groups of
control animals. When mice were maintained for an
additional 7 days after the last DT injection (day 21),
the mean BAL fluid PAI-1 concentration in DTR+ mice
remained elevated but was no longer statistically dif-
ferent from the control groups.
Lung collagen content
After determining that DT-mediated type II alveo-
lar epithelial cell injury induced intrapulmonary PAI-1
production in DTR-expressing mice, we next investi-
gated whether PAI-1 deficiency would protect against
the resultant lung collagen accumulation that occurs
in this model. To address this question, we admin-
istered DT for 14 days at a dose of 12.5 μg/kg to
DTR+ mice that were transgenically deficient in PAI-
1 (DTR+: PAI-1−/−). The extent of lung fibrosis in
these animals following DT treatment was then com-
pared to DT-treated DTR-expressing mice that were
WT for PAI-1 (DTR+: PAI-1+/+). Control groups of
mice included DT-treated DTR− mice that were either
WT or deficient in PAI-1 expression (DTR−: PAI-1+/+
and DTR−: PAI-1−/−). We also included a group of
DTR−: PAI-1+/+ mice that was treated for 14 days
with i.p. PBS to establish baseline lung collagen levels.
To quantify the extent of fibrosis, we harvested lungs
and measured lung hydroxyproline on day 21 (7 days
after the last DT treatment). We chose day 21 based on
our prior report that demonstrated a 1.5–2-fold increase
in lung collagen content in DT-treated DTR+ mice at
this time point. Consistent with these previously pub-
lished data, we found that targeted type II cell injury
caused a significant increase in lung hydroxyproline
content in the DTR+: PAI-1+/+ mice (Figure 2). Also
consistent with our previous results, mice that do not
express DTR and are WT for PAI-1 had no change
in their lung collagen content following DT injection.
Finally, we found that PAI-1 deficiency significantly
protected DTR-expressing mice from DT-induced lung
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Figure 1. PAI-1 protein concentrations increase in mice with DT-
mediated alveolar injury. Diphtheria toxin was administered daily
(12.5 μg/kg in 100 μl PBS by the i.p. route) for 14 days to either
DTR− or DTR+ mice. An additional control group of DTR− mice were
injected with 100 μl PBS for 14 days. BAL fluid was collected from
each animal after the last DT injection on day 14 (A) and 1 week
after the last DT injection on day 21 (B) and assayed by ELISA
for PAI-1 protein concentration. Results are reported as mean ±
SEM (n = 6). Groups are compared with a one-way ANOVA and a
Newman–Kuels post hoc multiple comparison test.
fibrosis. Importantly, in parallel studies, we also deter-
mined that PAI-1 deficiency significantly limited day
21 and day 28 lung collagen accumulation in DTR+
animals following 14 days of treatment with lower-
dose DT(10.0 μg/kg) (data not shown).
Survival
We previously reported a 25% mortality rate over
21 days in DT-treated DTR+ mice that received
14 days of treatment with the 12.5 μg/kg dose. In the
current study, the 12.5 μg/kg dose again induced a 25%
mortality in the DTR+: PAI-1+/+ animals. Another
35% of this group demonstrated significant weight
Figure 2. PAI-1 promotes lung collagen deposition following type
II AEC injury. Diphtheria toxin (12.5 μg/kg) was administered for
14 days/protocol to four strains of mice: 1, DTR−: PAI-1+/+; 2,
DTR−: PAI-1−/−; 3, DTR+:PAI-1+/+; and DTR+: PAI-1−/−. An
additional group of control DTR−: PAI-1+/+ received daily i.p.
injections of PBS for 14 days. Lungs were harvested on day 21 and
analysed for hydroxyproline content. Results are reported as mean
concentration (in μg/ml) ± SEM (n = 6–8). Groups are compared
with a one-way ANOVA and a Newman–Kuels post hoc multiple
comparison test.
loss (> 5.0 g) at the end of the 21 day experimental
period. These animals appeared pre-morbid and would
have required euthanasia if the experimental period
had continued for longer than 3 weeks (see Support-
ing information, Supplementary materials and methods,
and Figure S1). In contrast, the DTR+: PAI-1−/− group
experienced no mortality at day 21 and the largest
weight loss of any single animal in this group was
only 1.4 g.
Lung histology
To complement the quantitative hydroxyproline data
on which statistical analyses were performed, we
compared day 21 lung histology sections (two repre-
sentative samples from each group) from the follow-
ing three groups of mice following 14 days of DT
treatment (10 μg/kg dose): (a) control mice (DTR−:
PAI-1+/+); (b) DTR+: PAI-1+/+ mice; and (c) DTR+:
PAI-1−/− mice. Sections were stained with both
Masson’s trichrome (Figure 3A) and picrosirius red
(Figure 3B) techniques. As expected, lung sections
from DT-treated control mice (DTR−) revealed no evi-
dence of lung injury or fibrosis (Figure 3A, top panels).
In contrast, DT-treated DTR+: PAI-1+/+ mice demon-
strate diffuse alveolar wall thickening with prominent
blue staining and an accumulation of large cells with
macrophage morphology (Figure 3A, middle panels).
In contrast to the histological appearance of the DTR+:
PAI-1+/+ lung sections, the DTR-expressing mice that
were PAI-1-deficient (DTR+: PAI-1−/−) had no appre-
ciable fibrotic lesions (Figure 3A, bottom panels) and
were indistinguishable from the control group. These
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 228: 170–180
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
174 JJ Osterholzer et al
A
B
Figure 3. PAI-1 is associated with histopathological changes of pulmonary fibrosis following type II AEC injury. Diphtheria toxin
(10.0 μg/kg) was administered for 14 days/protocol to three strains of mice: 1, DTR−: PAI-1+/+; 2, DTR+: PAI-1+/+; and 3, DTR+:
PAI-1−/−. On day 21, lungs were harvested and 5 μm sections were generated for (A) Masson trichrome staining and (B) picrosirius red
staining (DTR+: PAI-1+/+ and DTR+: PAI-1−/− groups only). Representative images are shown for two mice in each group, taken with a
×20 objective (Masson trichrome staining) and a ×40 objective (picrosirius red staining).
differences were further appreciated with collagen-
specific picrosirius red staining (Figure 3B).
Immunostaining for PAI-1
Our observation that PAI-1 levels were increased in
the lavage fluid of DT-treated DTR+ mice led us to
hypothesize that the injured type II alveolar epithe-
lium may be a source of the PAI-1 production. We
thus performed immunofluorescence with antibodies to
PAI-1 and SPC on day 21 lung sections from three
groups of DT-treated mice: (a) DTR−: PAI-1+/+ mice;
(b) DTR+: PAI-1+/+ mice; and (c) DTR+: PAI-1−/−
mice (Figure 4). Images were then merged in order to
assess for cells that stained positively for both mark-
ers. In the lung sections obtained from DT-treated
DTR−: PAI-1+/+ control mice (Figure 4, top panels),
a modest amount of PAI-1 staining was appreciable
in SPC-expressing cells. In the lung sections obtained
from DT-treated DTR+: PAI-1+/+ mice, we found PAI-
1 staining to be increased throughout the interstitium
of the lung and within specific cells (Figure 4, mid-
dle panels). Some of these PAI-1-expressing cells also
stained positively for SPC, whereas other cells were
negative for SPC. Lung sections taken from DT-treated
DTR+: PAI-1−/− mice displayed minimal immunoflu-
orescence for PAI-1 as expected (Figure 4, bottom pan-
els). On the other hand, more prominent SPC staining
was observed in the DTR+: PAI-1−/− group compared
to the DT-treated DTR+/PAI-1+/+ mice, suggesting
that PAI-1 deficiency may enhance the recovery of type
II cells following DT treatment.
PAI-1 expression by injured type II alveolar
epithelial cells
To verify that DT-mediated injury enhances PAI-1
expression by type II AECs, we employed two separate
experimental approaches. First, we isolated type II
AECs from DTR+ and DTR− mice and cultured
them in vitro. After 48 h, we exposed subsets of the
transgenic and WT cells to DT for 24 h. The cells
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Figure 4. PAI-1 staining localizes to SPC-positive and SPC-negative cells following type II cell injury. Diphtheria toxin (10.0 μg/kg) was
administered for 14 days/protocol to three strains of mice: 1, DTR−: PAI-1+/+; 2, DTR+: PAI-1+/+; and DTR+: PAI-1−/−. On day 21, lungs
were harvested and 5 μm sections were generated for PAI-1 and SPC immunofluorescence (n = 2–3). The primary antibodies to SPC were
tagged with a green fluorescent protein and the primary antibody to PAI-1 was tagged with a red fluorescent antibody. Representative
images from an individual mouse in each group are shown.
were then harvested for RNA and PAI-1 message level
was measured using qualitative RT–PCR. We then
compared the expression of treated versus untreated
cells from each group. As demonstrated in Figure 5A,
DT-injured DTR+ cells had a significant increase in
PAI-1 message compared to unexposed controls. In
contrast, non-transgenic cells showed a decrease in
PAI-1 expression following DT treatment, and the
difference in response between the two groups was
highly statistically significant.
With the second approach, we isolated type II
alveolar epithelial cells from DTR+ and DTR− mice
following 14 days of diphtheria toxin treatment. Type
II cells were also collected from a control group of
DTR− mice that received 14 days of i.p. saline. The
cells from each group of mice were then cultured for
3 days prior to harvesting RNA for the quantification
of PAI-1 message levels. The relative PAI-1 expression
of our two DT treatment groups was compared to
the uninjured control cells. We again found that mean
PAI-1 mRNA expression was increased in the injured
DTR+ AECs as compared to the DTR− cells, although
in this set of experiments the difference did not reach
statistical significance (Figure 5B).
PAI-1 expression by lung macrophages
Our data indicate that type II AECs are a source
of PAI-1 in response to DT-mediated injury of the
alveolar epithelium. However, PAI-1 immunostain-
ing also suggested an additional cellular source of
expression in these mice. Many of these PAI-1-
positive : SPC-negative cells appeared large, and their
microanatomical location suggested a macrophage ori-
gin (Figure 4, middle panels). To determine whether
lung macrophages expressed PAI-1, we isolated two
subpopulations of cells from DTR− and DTR+ mice
on day 14 of DT treatment (ie the time-point of
maximal PAI-1 expression). These subsets included
alveolar macrophages (large autofluorescent cells
expressing CD11c but not CD11b) and exudate macro-
phages (large autofluorescent cells expressing both
CD11c and CD11b) [38,40,41]. Both isolated sub-
sets consisted of large cells with abundant cytoplasm
and occasional intracellular vacuoles (Figure 6A, B).
Expression of PAI-1 mRNA was detectable using
qRT–PCR in both populations but appeared consis-
tently higher in the exudate macrophages (Figure 6C).
PAI-1 mRNA expression was comparable within each
macrophage subset obtained from the DTR+ and
DTR− groups.
Exudate macrophage accumulation
Because the relative expression of PAI-1 was similar
in the exudate macrophages from the DTR− and
DTR+ mice, we hypothesized that, if these cells were
contributing to the increased BAL PAI-1 levels in
the DTR+ group, it may have been due to their
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Figure 5. Epithelial cells express PAI-1 following DT-mediated
injury. (A) Type II alveolar epithelial cells were isolated from
DTR− and DTR+ mice. 5.0 × 105 cells were plated in wells
precoated with fibronectin. After 48 h, a subset of cells from
each genotype was exposed to DT (1.0 μg/ml) for 24 h. RNA was
harvested from the cells and PAI-1 expression was assessed via
qRT–PCR and normalized to GAPDH. PAI-1 message levels from
the treated cells were compared to untreated cells of the same
genotype. Data are given as mean relative expression ± SEM,
n = 10/group. (B) Diphtheria toxin (10.0 μg/kg) was administered
for 14 days/protocol to DTR− (n = 3) and DTR+ mice (n = 3). A
control group of DTR− mice was treated with PBS for 14 days.
Type II AECs were isolated from each group and 2.0 × 106 cells
were cultured in fibronectin-coated wells. After 48 h, RNA was
harvested from the cells and PAI-1 expression was assessed via
qRT–PCR and normalized to GAPDH. PAI-1 message levels from the
DT-treated groups were compared to the control. Data are given as
mean relative expression ± SEM, n = 3/group.
increased lung accumulation. To test this hypothesis,
we quantified the number of exudate as well as alveolar
macrophages within lung leukocyte populations from
DT-treated DTR−: PAI-1+/+, DTR+: PAI-1+/+ and
DTR+: PAI-1−/− mice on day 14. We found that
the alveolar macrophage population was not different
between the three groups (Figure 7A). In contrast,
exudate macrophage numbers increased significantly
in the lungs of the DT-treated DTR+: PAI-1+/+ mice
compared to the control group (Figure 7B). In the
absence of PAI-1, however, exudate macrophages did
not accumulate in DTR-expressing mice following DT
injury (Figure 7B).
Exudate macrophages are derived from Ly6Chigh
monocyte precursors [38,40]. To determine whether
PAI-1 deficiency impacted exudate macrophage accu-
mulation by regulating the recruitment versus the
differentiation of Ly6Chigh monocytes, we next




Figure 6. Alveolar and exudate lung macrophages express PAI-
1. (A–C) Diphtheria toxin (10.0 μg/kg) was administered for
14 days/protocol to DTR− (n = 3) and DTR+ mice (n = 3). Lung
leukocytes from each strain of mice were isolated, pooled and
antibody stained as described in Materials and methods. Multi-
parameter fluorescence-activated cell sorting was performed to
eliminate non-macrophage populations and to further isolate
two populations of autofluorescent lung macrophages: CD11c+
CD11b− alveolar macrophages and CD11c+ CD11b+ exudate
macrophages. (A, B) Photomicrographs (taken with a ×1000
objective) of sorted alveolar macrophages (A) and exudate
macrophages (B). RNA was harvested from each macrophage
subset and PAI-1 mRNA expression was assessed via qRT–PCR
and normalized to GAPDH (C). Light grey bars, WT/DT; medium grey
bars, DT/DTR+.
treatment. As demonstrated in Figure 7C, the num-
ber of Ly6Chigh monocytes was significantly increased
in the DTR+ mice as compared to WT mice fol-
lowing alveolar injury. In contrast, the accrual of
this precursor monocyte population in PAI-1-deficient
DTR-expressing mice was significantly impeded. This
observation supports the conclusion that PAI-1 en-
hances the accumulation of exudate macrophages fol-
lowing type II AEC injury by facilitating Ly6Chigh
monocyte recruitment.
Collagen production by exudate macrophages
We next assessed whether the lung macrophage pop-
ulations of interest directly expressed collagen. First,
we performed qRT–PCR to quantify type-1 colla-
gen expression by alveolar and exudate macrophages
isolated from the lungs of DT-injured DTR− and
DTR+ mice. The results showed that both alveo-
lar macrophages and exudate macrophages express
collagen-1 mRNA with higher levels observed in the
exudate subset (Figure 8A).
We next used intracellular staining for collagen-1
to determine whether gene expression correlated with
the presence of protein in the DT-treated DTR−: PAI-
1+/+, DTR+: PAI-1+/+ and DTR+: PAI-1−/− groups
on day 14. Although we observed that a substantial
percentage (16–19%) of alveolar macrophages stained
for intracellular collagen (Col1+; Figure 8B), neither
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Figure 7. PAI-1 mediates the accumulation of exudate macrophages and Ly-6Chigh monocytes following alveolar injury. Diphtheria toxin
(10.0 μg/kg) was administered for 14 days/protocol to three strains of mice: 1, DTR−: PAI-1+/+; 2, DTR+: PAI-1+/+; and DTR+: PAI-1−/−.
Lung leukocytes from individual mice were isolated and antibody stained. Multi-parameter flow cytometric analysis was used to identify
and enumerate total numbers of alveolar macrophages (A), exudate macrophages (B) and Ly-6Chigh monocytes (C). Data are given as mean
± SEM of nine DT-treated mice/strain (from two separate experiments), assayed individually; light grey bars, DT/WT; medium grey bars,
DT/DTR+; and dark grey bars, DT/DTR+/PAI-1−. Values of p < 0.05 compared by unpaired Student’s t-test between groups at the same
time point were considered significant.
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Figure 8. PAI-1 mediates the specific accumulation of collagen-
1-positive exudate macrophages in mice with DT-mediated alveoli.
(A) Specific subsets of either alveolar macrophages or exudate
macrophages were isolated (by cell sorting, as described in
Materials and methods and Figure 8) from the lungs of DT-
treated DTR− (light grey bars) and DTR- (medium grey bars) mice,
and expression of Collagen-1 mRNA was assessed by qRT–PCR
(normalized to GAPDH). (B) Diphtheria toxin (10.0 μg/kg) was
administered for 14 days/protocol to three strains of mice: 1,
DTR−: PAI-1+/+; 2, DTR+: PAI-1+/+; and 3, DTR+: PAI-1−/−. Lung
leukocytes from individual mice were isolated and antibody stained,
using a protocol identifying intracellular collagen-1 protein.
Multi-parameter flow cytometric analysis was used to identify
and enumerate total numbers of collagen-1-positive alveolar
macrophages or exudate macrophages. Data are given as mean ±
SEM of nine DT-treated mice/strain, from two separate experiments,
assayed individually. Light grey bars, DT/DTR−; medium grey bars,
DT/DTR+; and dark grey bars, DT/DTR+/PAI-1−). Values of p < 0.05
compared by unpaired Student’s t-test between groups at the same
time point were considered significant.
the percentage nor the total number of Col1+ alve-
olar macrophages were increased in the DT-treated
DTR+: PAI+/+ mice relative to the other groups. In
contrast, a higher percentage of exudate macrophages
stained for intracellular collagen (relative to alveo-
lar macrophages), with a trend towards the highest
percentage of Col1+ staining being observed in exu-
date macrophages obtained from DT-treated DTR+:
PAI-1+/+ mice (33 ± 4%) [as compared to DT-treated
controls (27 ± 4%; p = 0.28) and DTR+: PAI-1−/−
mice (25 ± 2%; p = 0.09)]. Lastly, we calculated the
total numbers of each Col1+ macrophage subset. We
found no difference in the number of Col1+ alveo-
lar macrophages between the three groups. In con-
trast, the total number of Col1+ exudate macrophages
was significantly higher in the DT-treated DTR+: PAI-
1+/+ mice relative to DT-treated control and DTR+:
PAI-1−/− groups.
Discussion
The role of PAI-1 in the pathogenesis of lung fibrosis
was investigated using our model of fibrosis, initiated
by targeted type II alveolar epithelial cell injury. We
showed that an insult to the type II epithelium signif-
icantly induces PAI-1 expression in the lung. We also
demonstrated that mice deficient in PAI-1 are markedly
protected from epithelial injury-induced lung collagen
accumulation and mortality. Furthermore, we deter-
mined that the cellular source of PAI-1 production in
response to injury includes the type II AECs and two
populations of lung macrophages—alveolar and exu-
date macrophages. In addition, we report the novel
findings that PAI-1 itself mediates the accumulation
of exudate macrophages and that these cells produce
type I collagen. Lastly, our data revealed a strong
association between the accumulation of the exudate
macrophages and the development of pulmonary fibro-
sis in response to alveolar injury.
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Prior to the initiation of these experiments, the direct
relationship between PAI-1 levels and the severity
of pulmonary fibrosis had been established entirely
in the bleomycin model. Therefore, the possibility
remained that the causal link was dependent on fea-
tures unique to bleomycin injury. As such, a pri-
mary goal of this study was to determine whether
PAI-1 influenced the development of pulmonary fibro-
sis in a separate and mechanistically distinct murine
model. To accomplish this goal, we employed our
recently described type II AEC injury model. With
this model, we found that DT-mediated type II epithe-
lial cell damage leads to an increase in the quantity
of PAI-1 within bronchoalveolar lavage fluid. This
induction of PAI-1 expression mimics the elevated lev-
els of intrapulmonary PAI-1 observed in patients with
pulmonary fibrosis of varying aetiologies [14–16,18].
PAI-1 production is also increased in the lung fol-
lowing bleomycin-mediated injury [19,20,22–26,42].
To determine whether the enhanced PAI-1 production
following type II AEC injury was required for fibro-
genesis, we generated transgenic mice that expressed
human DTR on their type II AECs and were deficient
in PAI-1. We found that PAI-1 deficiency conferred sig-
nificant protection in these mice against DT-mediated
pulmonary fibrosis. In fact, the lung hydroxyproline
and histology in the DTR+: PAI-1−/− mice was not
different from the control DTR−: PAI-1−/− group.
Importantly, PAI-1 deficiency also limited the mor-
bidity/mortality that results from the targeted type II
cell insult. This decreased morbidity/mortality in the
DT-treated DTR+: PAI-1−/− mice is reminiscent of
that observed in PAI-1-deficient mice following both
bleomycin- and hyperoxia-induced lung injury [25,43].
Of note, PAI-1 inhibition was very recently reported
to reduce fibrosis in yet another model of pulmonary
fibrosis, intrapulmonary TGFβ over-expression [28].
Together, these observations provide very strong evi-
dence substantiating a critical and fundamental role for
PAI-1 in the pathogenesis of pulmonary fibrosis.
Aspects of our animal model are distinct from
bleomycin-mediated injury and share features of patho-
genesis with the human disease which contribute to the
significance of our findings. Most importantly, the DTR
model recapitulates the epithelial injury that is such
a prominent histopathological feature of the human
disease [30–32]. In fact, the generation of our DTR
model was motivated by a popular hypothesis that
type II AEC defects are critical for the development of
lung fibrosis [32]. This hypothesis is supported by the
consistently recognized abnormalities (eg denudation
and hypertrophy) in the alveolar epithelium overlying
fibroblast foci, the purported lesion of active scarring.
The association between mutations in type II alveolar
epithelial cell-specific genes and the development of
familial IPF lends additional credence to this hypoth-
esis [33,34]. Because the type II AEC injury model
shares pathogenic features with IPF, we believe our
data enhance the relevance of PAI-1 as a potential ther-
apeutic target.
Our data revealed that at least two cellular sources,
type II AEC and lung macrophages, contribute to the
increased PAI-1 levels in the alveolar compartment of
DT-injured DTR+ mice. As with our original report,
we again observed persistent SPC-expressing cells in
the lungs of DTR+ mice following DT administration.
Importantly, these residual type II AECs contribute
to the pro-fibrotic milieu through their production of
PAI-1. Consistent with published literature, our present
data indicate that these cells are not the only source
of PAI-1 in the injured lung. In addition to type
II AECs, we found that macrophages also produce
PAI-1. This latter observation is consistent with data
from the bleomycin model, in which microdissected
type II AECs expressed ∼10-fold higher levels of
PAI-1, while macrophages obtained either by lavage
or by microdissection expressed ∼20–60-fold higher
PAI-1 levels [44]. In the present study, we further
defined the production of PAI-1 by macrophage subsets
and found that the accumulated non-resident exudate
population most strongly expressed PAI-1. Although
our results clearly implicate type II AECs and exudate
macrophages as important sources of PAI-1 in the lung
following a targeted epithelial injury, our results do
not exclude the participation of other cells, such as
fibroblasts, in the production of PAI-1.
Although many studies implicate PAI-1 as a potent
fibrogeneic mediator, the elucidation of its mecha-
nism of action in promoting collagen accumulation has
been elusive. Herein, we provide results that further
clarify the role PAI-1 in fibrogenesis. We report the
novel finding that PAI-1 is necessary for the accumu-
lation of exudate macrophages in the lung following
type II AEC injury. These cells express collagen 1
mRNA and stain for intracellular collagen, suggest-
ing that they contribute directly to the fibrotic pro-
cess. Our data reveal that PAI-1 facilitates the accrual
of exudate macrophages by mediating the recruit-
ment of Ly6Chigh monocytes, the precursor of exudate
macrophages, into the injured lung. There exist many
plausible mechanisms by which PAI-1 might influence
this monocyte recruitment. For example, PAI-1 may
enhance the transendothelial migration of Ly6Chigh
monocytes across the pulmonary vasculature (perhaps
through its vitronectin-binding function) [42]. Alterna-
tively, PAI-1 may alter the expression or recognition of
monocyte/macrophage chemotactic factors (ie CCL2 or
CCL7). A potential effect of PAI-1 on monocyte devel-
opment within the bone marrow also warrants consid-
eration. Future studies are planned to further delineate
these potential mechanisms.
In summary, we have determined that a targeted
type II cell injury leads to the significant induction of
PAI-1 and that PAI-1 is necessary for the subsequent
fibrotic response. These findings establish a causal
role for PAI-1 in a model of pulmonary fibrosis other
than bleomycin, and implicate PAI-1 as a central
component of the fibrogenic pathway. Our data further
implicate the PAI-1 mediated accumulation of exudate
macrophages as one potential mechanism whereby
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PAI-1 contributes to the development of lung fibrosis.
Ultimately these findings further motivate the targeting
of PAI-1 as a therapeutic strategy for human fibrotic
disorders.
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